Investors focused on the Medical space have likely heard of Ionis Pharmaceuticals (IONS), but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Ionis Pharmaceuticals is a member of our Medical group, which includes 841 different companies and currently sits at #1 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. IONS is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for IONS's full-year earnings has moved 1.42% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, IONS has moved about 8.66% on a year-to-date basis. At the same time, Medical stocks have gained an average of 3.81%. This means that Ionis Pharmaceuticals is performing better than its sector in terms of year-to-date returns.
Breaking things down more, IONS is a member of the Medical - Drugs industry, which includes 179 individual companies and currently sits at #77 in the Zacks Industry Rank. On average, this group has gained an average of 8.73% so far this year, meaning that IONS is slightly underperforming its industry in terms of year-to-date returns.
IONS will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.